Drug Search Results
More Filters [+]

INO-3401

Alternative Names: ino-3401, ino3401, ino 3401
Latest Update: 2017-09-13
Latest Update Note: Clinical Trial Update

Product Description

H1 and H5 Influenza Hemagglutinin Plasmid Vaccine (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01405885)

Mechanisms of Action: Vaccine

Novel Mechanism: No

Modality: Vaccine

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Inovio
Company Location: SAN DIEGO CA 92121
Company CEO: Jacqueline E. Shea
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for INO-3401

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Influenza, Human

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

FLU-002

P1

Completed

Influenza, Human

2012-08-01

Recent News Events

Date

Type

Title